Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy [Seeking Alpha]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Seeking Alpha
ELEVIDYS, despite not meeting its primary endpoint in the Phase III trial, showed significant improvements in motor function and secondary endpoints, keeping the potential for label expansion alive. SRPT's growth prospects, including potential label expansion for ELEVIDYS, have led to an updated strategy and bullish outlook for the company. Looking for a portfolio of ideas like this one? Members of Compounding Healthcare get exclusive access to our subscriber-only portfolios. Learn More » In my last Sarepta Therapeutics ( NASDAQ: SRPT article , I discussed Sarepta's Q3 performance and their clinical progress in Duchenne muscular dystrophy (DMD) and other rare diseases. At that time, Sarepta had recently revealed their Q3 product revenue was up 49% year-over-year, aided by ELEVIDYS, which pulled in $69.1M in its first quarter on the market. Unfortunately, ELEVIDYS' Phase III EMBARK trial failed to hit its primary endpoint, generating an abrupt sell-off for SRPT. However, the mar
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings [Yahoo! Finance]Yahoo! Finance
- Bullish Sarepta Therapeutics Insiders Loaded Up On US$13.3m Of Stock [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics to Announce First Quarter 2024 Financial ResultsBusiness Wire
- GSK Gears Up for Q1 Earnings: Here's What to Expect [Yahoo! Finance]Yahoo! Finance
- IRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in Columbus [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 2/28/24 - Beat
SRPT
Sec Filings
- 4/24/24 - Form DEF
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- SRPT's page on the SEC website